WORLD LEADING PARASITOLOGY AND MYCOLOGY TEST KITS
RAPID LATERAL FLOW TEST FOR BRUCELLA CANIS NOW AVAILABLE
Q-TOX FACTOR-X ACTIVATOR RVV-X NOW AVAILABLE
COST EFFECTIVE VETERINARY DIAGNOSTICS NOW AVAILABLE
Featured Products
Our Product Ranges
Recieve our latest news
Sign up to our newsletterOur Company
With over 30 years of trading experience, Quadratech Diagnostics Limited has always been and remains committed to providing the highest quality state-of-the-art medical diagnostic and research products. Since the company was founded in 1990, we have expanded to encompass the following main areas: Haemostasis, Antigens, Antibodies and Toxins, Rapid and POC Tests, Parasitology and Veterinary.
Quadratech Diagnostics Limited is a corporate member of the Institute of Biomedical Scientists (IBMS) and the British Society for Haemostasis and Thrombosis (BSHT). We are a recognised supplier to the UK National Health Service (NHS), the Irish Health Service Executive (HSE), private laboratories, the UK pharmaceutical industry, and university research groups. Quadratech Diagnostics Limited became incorporated as a limited company in 1998 and is ISO 9001:2015 certified.
Our Product Brands
Latest News
Haemostasis Q3 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q3 2025. REGULATORY Novo Nordisk’s Alhemo (concizumab-mtci, a tissue factor pathway inhibitor antagonist) injection received positive opinion by the EMA CHMP, recommending label expansion to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors (25 Jul) Kedrion […]
Haemostasis Q2 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q2 2025, including the latest data presentations at ISTH 2025. REGULATORY FDA approved Bayer’s Jivi (a recombinant extended half-life factor VIII concentrate) for use in paediatric patients 7 years of age and older with haemophilia A based on Alfa-PROTECT and PROTECT Kids trial […]
Virus-like particles for vaccine R&D and diagnostic assays
Virus-like particles (VLPs) are self-assembled protein nanoparticles that closely resemble viruses, but contain no viral genetic material and are replication-deficient. First discovered in 1968 in sera of patients infected with Hepatitis B virus, VLPs have since become vital tools for scientific and translational research in biology and medicine. The utility of VLP technology has expanded […]
